Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors
This study is testing a new experimental cancer drug called VT3989, either by itself or mixed with other standard cancer treatments. Researchers want to find the safest and most effective dose for people with advanced solid tumors or mesothelioma.
You might qualify if you have advanced solid tumors or mesothelioma that has not responded well to standard treatments. Participants must also have generally healthy organ function and measurable tumors.
You will receive the study medication, VT3989, taken by mouth once a day, and possibly other approved cancer therapies. Your medical team will closely monitor your health, side effects, and how your tumor responds through regular check-ups and lab tests.
This study is currently recruiting patients and is taking place at medical centers in major cities including San Francisco, Chicago, and Boston. Your study doctor can provide the exact location details closest to you.
- 1Testing a new experimental drug named VT3989 for advanced cancers
- 2Open to patients with specific solid tumors or mesothelioma
- 3Currently recruiting participants at select locations across the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.